Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexocyclium SCHEMBL934371 | 0.90 | CHRM2 (1.00) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL5166775 | 0.83 | CHRM2 (0.74) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL11879574 | 0.82 | CHRM2 (0.72) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Hexocyclium SCHEMBL4323226 | 0.81 | CHRM2 (0.81) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Hexocyclium SCHEMBL25730 | 0.81 | CHRM2 (0.81) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL10518509 | 0.79 | CHRM2 (0.68) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL7818482 | 0.79 | CHRM2 (0.52) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Hexocyclium SCHEMBL10747435 | 0.78 | CHRM2 (0.76) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL10519164 | 0.78 | CHRM2 (0.67) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL10519217 | 0.76 | CHRM2 (0.64) | CHRM2CHRM1KCNH2CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| US-5153205-A | Administering cholinergic M3 receptor antagonist along with cholinomimetic agent | MERCK & CO., INC. (US) | 1992-10-06 | — | — | US | claimed |
| EP-0479524-A1 | Method to reduce intraocular pressure without causing miosis | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| EP-4537829-A2 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | University Of Manitoba (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20250090545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | UNIV MANITOBA (CA) | 2025-03-20 | — | — | US | disclosed |
| EP-3363439-B1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIV MANITOBA (CA) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180922-A1 | TREATMENTS FOR DIABETIC NEUROPATHY | UNIV MANITOBA (CA) | 2024-06-06 | — | — | US | disclosed |
| US-11925649-B2 | Treatments for diabetic neuropathy | UNIVERSITY OF MANITOBA (CA) | 2024-03-12 | — | — | US | disclosed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190046540-A1 | TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-14 | — | — | US | disclosed |
| EP-3363439-A2 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | University Of Manitoba (CA) | 2018-08-22 | — | — | EP | disclosed |
| US-20170027957-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-02 | — | — | US | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20130289019-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | Amazing Grace, Inc. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY OF MANITOBA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-5153205-A | Administering cholinergic M3 receptor antagonist along with cholinomimetic agent | MERCK & CO., INC. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0479524-A1 | Method to reduce intraocular pressure without causing miosis | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | CHRNA5, CHRM2, GAP43 | CHRM2 2/4885CHRM1 18/4885KCNH2 57/4885 |
| US-20170027957-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | PMP22, CHRNA7, CHRNB3 | CHRM2 12/4885CHRM1 35/4885KCNH2 1073/4885 |
| US-20250090545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | PMP22, CHRNA7, CHRNB3 | CHRM2 12/4885CHRM1 35/4885KCNH2 1073/4885 |
| US-11925649-B2 | Treatments for diabetic neuropathy | CHRNA5, CHRNE, CHRM2 | CHRM2 3/4885CHRM1 19/4885KCNH2 69/4885 |
| US-20190046540-A1 | TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | CHRNA5, CHRM2, CHRNE | CHRM2 2/4885CHRM1 15/4885KCNH2 62/4885 |
| US-20240180922-A1 | TREATMENTS FOR DIABETIC NEUROPATHY | CHRNA5, CHRNE, CHRM2 | CHRM2 3/4885CHRM1 19/4885KCNH2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.